Lantheus_Logo.png
Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
September 15, 2024 08:45 ET | Lantheus Holdings, Inc.
Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3%...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
September 15, 2024 03:00 ET | MacroGenics, Inc.
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing...
MetasTx-Logo_HoRes.jpg
Harvey Homan to Highlight MetasTx’s Game-Changing Approach to Cancer Treatment at PA Life Science Futures
September 12, 2024 06:58 ET | MetasTx LLC
MetasTx aims to revolutionize cancer treatment by targeting p21-activated kinase (PAK-1), a critical driver of metastasis in solid tumors.
Tackling Prostate Cancer Disparities in Black Men
The National Civil Rights Museum Hosts Catalyst for Change Panel on Prostate Cancer Health Inequities in Black Men
September 10, 2024 16:22 ET | National Civil Rights Museum
Memphis, TN, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The National Civil Rights Museum (NCRM) is proud to present "Tackling Prostate Cancer Disparities in Black Men" as part of its Catalyst for Change...
Picture1.jpg
Curium Anuncia Que PYLCLARI®, un Innovador Trazador PET 18F-PSMA Indicado en Pacientes Con Cáncer De Próstata, Ya Está Disponible en España
September 10, 2024 04:30 ET | Curium US LLC
PARIS, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Curium, líder mundial en medicina nuclear, ha anunciado hoy que PYLCLARI ® ya está disponible en España para pacientes con cáncer de próstata. PYLCLARI®...
Picture1.jpg
Curium Announces PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer – Is Now Available in Spain
September 10, 2024 04:30 ET | Curium
CURIUM ANNOUNCES PYLCLARI® – AN INNOVATIVE 18F-PSMA PET TRACER INDICATED IN PATIENTS WITH PROSTATE CANCER – IS NOW AVAILABLE IN SPAIN
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
September 08, 2024 19:10 ET | MacroGenics, Inc.
ROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative...
biomerica.png
The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer
September 04, 2024 08:19 ET | Biomerica, Inc.
- 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi Arabia - Prostate Cancer is the Second Most Common Cancer in Men Globally ...
Movember_Primary Logo_Black.jpg
Movember Announces Three Year Partnership With the International Society for Sexual Medicine
September 04, 2024 07:00 ET | Movember Canada
Movember is kicking off Prostate Cancer Awareness Month by announcing a new three-year partnership with the International Society for Sexual Medicine.
North American Cancer Biopsy Market
North America Cancer Biopsy Market Research Report 2024
August 28, 2024 11:10 ET | Research and Markets
Dublin, Aug. 28, 2024 (GLOBE NEWSWIRE) -- The "North America Cancer Biopsy Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...